Adenosine A(2A) receptor activation reverses hypoxia-induced rat pulmonary artery smooth muscle cell proliferation via cyclic AMP-mediated inhibition of the SDF1-CXC4 signaling pathway

作者：Wang, Yang; Ying, Lei; Jin, Ke-Ke; Nan, Yan; Hu, Suhua; Wu, Xueqin; Qi, Ruyi; Luo, Xin; Wang, Liangxing^*

来源：International Journal of Molecular Medicine, 2018, 42(1): 607-614.

DOI：10.3892/ijmm.2018.3626

• adenosine A(2A) receptor
• hypoxia
• pulmonary artery smooth muscle cell proliferation
• cyclic adenosine monophosphate
• stromal cell-derived factor 1
• CXC chemokine receptor 4

The occurrence and the subsequent development of pulmonary arterial hypertension (PAH) involve complicated mechanisms. Of these, the proliferation of pulmonary artery smooth muscle cells (PASMCs) has been indicated to be closely associated with its progression. Therefore, therapeutic methods targeting PASMCs to inhibit proliferation is an effective method for alleviating PAH. The present study was designed to determine the role of the adenosine A(2A) receptor (A(2A) receptor) in hypoxia-induced rat PASMC (RPASMC) proliferation. Primary RPASMCs were isolated from the pulmonary artery of adult male SD rats, cultured and used for the following experiments. The mRNA level and protein expression of CXCR4 were measured by reverse transcription-quantitative polymerase chain reaction and western blot analysis, respectively. The cell proliferation of RPASMCs was measured using a cell proliferation assay kit. In the present study, it was demonstrated that the proliferation of RPASMCs was partially mediated by activation of the stromal cell-derived factor 1 (SDF1)-CXC chemokine receptor 4 (CXCR4) axis under hypoxic conditions. In addition, SDF1- alone upregulated the mRNA and protein expression levels of CXCR4, and stimulated the proliferation of RPASMCs. The protein expression of CXCR4 and the cell proliferation were markedly inhibited by application of A(2A) receptor agonist CGS21680 or cyclic adenosine monophosphate (cAMP) under hypoxic conditions or treatment with SDF1- and was reversed by the A(2A) receptor antagonist SCH58261 or 8-bromoadenosine-3,5-cyclic monophosphorothioate. These results demonstrated that the inhibition of SDF1-CXC4 signaling by the activation of A(2A) receptor and subsequent increase in the level of cAMP may be a potential method to ameliorate PAH.

• 出版日期2018-7
• 单位温州医科大学